Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Patent
1996-09-13
1998-06-30
Shah, Mukund J.
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
514212, 5142282, 5142288, 5142332, 514254, 540598, 544 584, 544 96, 544114, C07D40304, C07D41314, A61K 3150
Patent
active
057735301
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/JP94/02230, filed Dec. 26, 1994.
TECHNICAL FIELD
The present invention relates to a novel pyrazolopyridine compound or a pharmaceutically acceptable salt thereof which are useful as a medicament.
BACKGROUND ART
Some pyrazolopyridine compounds to be useful as psychostimulant, antihypertensive agent, remedy for renal failure, diuretic, or the like are known (e.g. EP-0299209, EP-0379979, etc).
DISCLOSURE OF INVENTION
The present invention relates to a novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof useful as a medicament; the processes for the preparation of said pyrazolopyridine compound or a salt thereof; a pharmaceutical composition comprising, as an active ingredient, said pyrazolopyridine compound or a pharmaceutically acceptable salt thereof; a use of said pyrazolopyridine compound or a pharmaceutically acceptable salt thereof as a medicament; and a method for using said pyrazolopyridine compound for the therapeutic purpose, which comprises administering said pyrazolopyridine compound or a pharmaceutically acceptable salt thereof to a human being or an animal.
The pyrazolopyridine compound or a pharmaceutically acceptable salt thereof is an adenosine antagonist (especially, A.sub.1 receptor antagonist) and possesses various pharmacological actions such as cognitive enhancing action, analgesic action, locomotor action, antidepressant action, diuretic action, cardioprotective effect, cardiotonic action, vasodilating action (e.g. cerebral vasodilating action, etc), the action of increasing the renal blood flow, renal protective effect, improvement of renal function, enhancing action of lipolysis, inhibition of anaphylactic bronchoconstriction, acceleration of the insulin release, the action of increasing the production of erythropoietin, inhibiting action of platelet aggregation, or the like; useful as cognitive enhancer, antidementia drug, psychostimulant, analgesic, cardioprotective agent, antidepressant, ameliorants of cerebral circulation, tranquilizer, drug for heart failure, cardiotonic agent, antihypertensive agent, drug for renal failure (renal insufficiency), drug for renal toxicity, renal protective agent, drug for improvement of renal function, diuretic, drug for edema, antiobesity, antiasthmatic, bronchodilator, drug for apnea, drug for gout, drug for hyperuricemia, drug for sudden infant death syndrome (SIDS), ameliorants of immunosuppressive action of adenosine, antidiabetic agent, drug for ulcer, drug for pancreatitis, drug for Meniere's syndrome, drug for anemia; drug for arteriosclerosis obliterans, drug for thrombophlebitis, drug for cerebral infarction, drug for transient ischemic attack, drug for angina pectoris, or the like; (e.g. Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, etc), anxiety, pain, cerebrovascular disease (e.g. stroke, etc), hypertension, etc); circulatory insufficiency (acute circulatory insufficiency) cuased by, for example, the ischemia/reperfusion injury (e.g. myocardial ischemia/reperfusion injury, cerebral ischemia/reperfusion injury, peripheral ischemia/reperfusion injury, etc), shock (e.g. endotoxin shock, hemorrhagic shock, etc), surgical procedure, or the like; post-resuscitation asystole; bradyarrhythmia; electro-mechanical dissociation; hemodynamic collapse; gentamicin, FR-900506 (disclosed in EP-0184162), cyclosporin (e.g. cyclosporin A) or the like; glycerol, etc!, nephrosis, nephritis, edema (e.g. cardiac edema, nephrotic edema, hepatic edema, idiopathic edema, drug edema, acute angioneurotic edema, hereditary angioneurotic edema, carcinomatous ascites, gestational edema, etc); obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer such as peptic ulcer (e.g. gastric ulcer, duodenal ulcer, etc), pancreatitis, Meniere's syndrome, anemia; thrombosis, etc), obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack, angina pectoris, or the like.
The novel pyrazol
REFERENCES:
patent: 4925849 (1990-05-01), Shiokawa et al.
patent: 4985444 (1991-01-01), Shiokawa et al.
patent: 4994453 (1991-02-01), Shiokawa et al.
patent: 5087629 (1992-02-01), Shiokawa et al.
patent: 5102869 (1992-04-01), Shiokawa et al.
patent: 5102878 (1992-04-01), Shiokawa et al.
patent: 5155114 (1992-10-01), Shiokawa et al.
patent: 5179103 (1993-01-01), Shiokawa et al.
patent: 5204346 (1993-04-01), Shiokawa et al.
patent: 5234930 (1993-08-01), Shiokawa et al.
patent: 5296490 (1994-03-01), Shiokawa et al.
patent: 5338743 (1994-08-01), Shiokawa et al.
Akahane Atsushi
Durkin Kieran P. M.
Itani Hiromichi
Nishimura Shintaro
Coleman Brenda
Fujisawa Pharmaceutical Co. Ltd.
Shah Mukund J.
LandOfFree
Pyrazolopyridine adenosine antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolopyridine adenosine antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolopyridine adenosine antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1860346